Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Operating Income: 2019-2025

Historic Operating Income for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -$188.8 million.

  • Avidity Biosciences' Operating Income fell 92.40% to -$188.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$612.5 million, marking a year-over-year decrease of 88.63%. This contributed to the annual value of -$378.9 million for FY2024, which is 60.84% down from last year.
  • Avidity Biosciences' Operating Income amounted to -$188.8 million in Q3 2025, which was down 10.32% from -$171.1 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Operating Income registered a high of -$23.9 million during Q1 2021, and its lowest value of -$188.8 million during Q3 2025.
  • Moreover, its 3-year median value for Operating Income was -$82.6 million (2024), whereas its average is -$100.5 million.
  • Data for Avidity Biosciences' Operating Income shows a maximum YoY tumbled of 287.92% (in 2021) over the last 5 years.
  • Avidity Biosciences' Operating Income (Quarterly) stood at -$38.5 million in 2021, then tumbled by 38.08% to -$53.2 million in 2022, then dropped by 25.40% to -$66.7 million in 2023, then plummeted by 81.28% to -$121.0 million in 2024, then plummeted by 92.40% to -$188.8 million in 2025.
  • Its Operating Income was -$188.8 million in Q3 2025, compared to -$171.1 million in Q2 2025 and -$131.5 million in Q1 2025.